Joseph A. Markenson, MD

Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College
Attending Physician, Department of Medicine, Memorial Sloan-Kettering Cancer Center

Rheumatology

Internal Medicine

Crystalline Disease (Gout and pseudo gout)
Osteoarthritis
Rheumatoid Arthritis (RA)
Scleroderma
Systemic Lupus Erythematosus (SLE)
Vasculitis

Lupus Erythematosus Foundation Fellow, 1975-76
Diplomate, American Board of Internal Medicine, 1976
Diplomate, American Board of Internal Medicine, 1978
Master American College of Rheumatology, 2010

Subspecialty Board of Rheumatology, Member

Lupus and APS Center of Excellence

Aetna
Affinity Access
Blue Cross HMO POS
Blue Cross PPO
Blue Cross Pathway
Blue Cross Pathway Enhanced
Cigna
Emblem Selectcare
Medicare
Oxford
United Healthcare

If your particular insurance plan is not listed, you may still have coverage subject to the availability of 'out-of-network' benefits. Please do not hesitate to contact our office if you have questions regarding your insurance coverage.

MD, State University of New York-Downstate Medical Center, New York, 1970

The New York Hospital, Weill Cornell Medical College - Internal Medicine

Internal Medicine
Rheumatology

New York

Markenson, J.A.,Using the new biologic therapies in rheumatoid arthritis: practical aspects. Future Rheumatol 2(5), 475-483,2007

Markenson, J.A. Rheumatic Manifestations of endocrine diseases: Curr Opin Rheum 22:64-71,2010

Gibofsky, A., W.R.Palmer, E.C.Keystone., et al Rheunmatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the Radius 1 and Radius 2 Registries. J. Rheum. 2011 38(1) 21-28

Markenson, J.A.,A.G.Gibofsky,Palmer,W.R., et al Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observation from the RADIUS Registry. J.Rheum. 2011, 38(7) 1273-1281

Chakravarty,S.,D, and J.A.Markenson: Rheumatic Manifestations of Endocrine Disease: Curr Opin Rheum 2013,25:37-43

Markenson, J.A.,A.S.Koenig,Jing Yuan Feng, et al. Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. A Retrospective Analysis From the RADIUS Cohort. JCR:2013, 19 (6): 314-323

Markenson, J.A. Commentary on Review: Glucosamine and chondroitin,alone or in combination,do not clinically improve knee or hip pain in osteoarthritis. ACP Journal Club 2011,154;(3) JC3-4

Markenson, J.A.,Charalambous,K.,Wiereck,C.,et al US Rheumatologists’ Attitudes,Practice Habits,Barriers, and Knowledge Gaps in Assessing and Monitoring Patients with Rheumatoid Arthritis according to Recent Recommendations. CE Measure. 2013:7:87-95

Brostoff SW, Carlo DJ, Dively, et al:  Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides.  In Advances in Osteoarthritis.  Eds.  S. Tanka, C.  Hamanishi.  Tokyo: Springer-Verlag, 1999, pp 153-162.  .

Paget SA, Zuniga-Montes RL, Markenson JA and Bateman H.  Heel Pain in the Setting of Metabolic, Infiltrative, and Bone Disorders.  In Disorders of the Heel, Rearfoot and Ankle.  Eds.  C. Ranawat and R. Positano.  Philadelphia, PA: Churchill Livingstone, 1999, pp 172-179.

Paget S.A., Bateman, H. Markenson, J.A., and Zuniga-Motes, L.R. Heel Pain and Achilles Pain Associated with Rheumatoid Arthritis and Seronegative Spondyloarthropathies. In Disorders of the Heel, Rearfoot, and Ankle. Eds. C. Ranawat and R. Positano Churchill Livingstone Philadelphia Pa. 1999 pp180-187

Markenson JA.  Psoriatic Arthritis in Manual of Rheumatology and Outpatient Orthopedic Disorders.  Eds.  S.A. Paget, A. Gibofsky, and John F. Berry III.  Philadelphia, PA: Lippincott, Williams & Wilkins, 2000, pg. 279.

Markenson J.A. Guest Editor Rheumatic Disease Clinic of North America. Rheumatologic Manifestations of Endocrine Disease. Elsevier Volume 36,4,2010

Dr. Joseph Markenson is the principal investigator for drug studies involving patients with Rheumatic Diseases (Rheumatoid Arthritis, Osteoarthritis and Lupus). Ongoing recruitment for enrollment in studies currently active. Patients interested in more information or to participate in a Clinical Drug Trial should call his office at 212.606.1261.